开云·kaiyun(体育)官方网站-登录入口

BioHub portfolio

With 15 years + of experience in medtech incubation and investment, BioHub focuses on major unmet medical needs in China and searches for the disruptive innovation around the world. Relying on its ecosystem and its unique Incubation + Investment model, BioBub accelerates the development of the innovative healthcare startups.

CD Biopharma is committed to the development and commerciali···
CD Biopharma

Suzhou, China

Invested in 2021

IL-21 and PDL1 fusion protein

CD Biopharma

CD Biopharma is committed to the development and commercialization of innovative tumor immunotherapy drugs. The team is deeply engaged in the development of tumor immunotherapy drugs, especially the research on the cytokines. Based on its innovative ImmuX and FusionX platforms, CD Biopharma has developed novel therapeutic strategies to target specific T cells, and launched a number of first-in-class drugs.
MORE：http://cdvip.szyhdk.cn/
HROCT LITT Medtech has developed the unique SNP(Smart Needle···
HROCT LITT Medtech

Suzhou，China

Invested in 2022

Ultra-high resolution and ultra-high depth OCT imaging, integrating with low energy laser ablation

HROCT LITT Medtech

HROCT LITT Medtech has developed the unique SNP(Smart Needle Probe) needle imaging, assembled as catheter, which OD is smaller than 1/5 of the traditional invasive OCT catheter, while the depth and resolution are all multiple times of the traditional invasive OCT catheter, achieving 1um level to supply the histopathology needed microimaging. The fiber could be compatible with different kinds of biopsy needles to access the targets, also could be coupled with specific laser to achieve OCT situ diagnosis and laser ablation. Its technology provide revolutionary solutions to neuro surgery, interventional pulmonology, neurovascular, nephropathy, mammary gland, cardiac, GI and other fields.
MORE：
MedpaceMedtechfocuses on the treatment of functional and met···
Medpace Medtech

Hangzhou, China

Invested in 2018

Neuromodulation therapy of functional and metabolic diseases

Medpace Medtech

MedpaceMedtechfocuses on the treatment of functional and metabolic diseases by neuromodulation. Since inception, Medpace Medical has developed innovative applications of neuromodulation therapy in inflammatory bowel disease, diabetes and functional gastrointestinal diseases based on cutting-edge basic research carried out at demostic and abroad.
MORE：
Jasmine eye movement detector: The Jasmine project, led by a···
jasmine

Chengdu, China

Invested in 2018

jasmine

Jasmine eye movement detector: The Jasmine project, led by a team of professors from domestic universities, made progress in the research on the correlation between eye movement detection and analysis and Alzheimer's disease in 2015, got good feedback on trial in several clinical hospitals, published variable high-quality literature, and was approved with independent patents in 2018.
MORE：
Reunion Biotech focuses on the research and development and ···
Reunion Biotech

Shanghai, China

Invested in 2021

Medical hydrogels

Reunion Biotech

Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.
MORE：
ViewGene is a leading gene therapy company has developed a p···
ViewGene

Suzhou, China

Invested in 2021

Inducible and tissue-specific gene therapy

ViewGene

ViewGene is a leading gene therapy company has developed a proprietary inducible and tissue-specific gene therapy platform in China. The platform reduces the potential risks of uncontrollable dose and overexpression of gene expression and overcomes the shortcomings of traditional gene therapy techniques such as tissue destruction, immunogenicity, inflammatory response, and short onset time in vivo. The highlights of its gene therapy drugs are the clear dose-response relationship and high safety, which have significant advantages in the treatment of single-gene genetic diseases.
MORE：
Wuhan Baina Likang Biopharmaceutical Co., Ltd. was establish···
BAINA LIKANG

Wuhan,china

Invested in 2018

BAINA LIKANG

Wuhan Baina Likang Biopharmaceutical Co., Ltd. was established in 2017. The company has a high-quality professional and technical team, which is composed of overseas returned experts, doctors and experts with senior technical titles. The business backbone has many years of professional work experience. The employees have high professional knowledge and skills, and have profound experience and technical strength in the research and development, pilot test, and scale-up production of long-acting sustained release drugs. Bainarikang products adopt liquid crystal gel delivery technology, and are committed to changing and improving the existing medication methods. In the traditional administration mode, the drug utilization in the human body is not high, and the dosage once a day or even several times a day leads to low drug compliance of patients. Benalikang long-acting sustained release technology adopts the preparation method of liquid crystal gel. Once administered, the drug can be slowly released in the body for weeks to a month, and the carrier can be degraded and absorbed.
MORE：
PercAssist was founded in May 2022, invested by BlingStar Ve···
PercAssist

Suzhou, China

Invested in 2022

PercAssist

PercAssist was founded in May 2022, invested by BlingStar Venture Capital, and located in the Baichuanghui International Innovative Medical Transformation Base of Suzhou Hi tech Zone, and is committed to building an innovative technology platform for interventional therapy around heart failure. PercAssist is led by senior R&D teams of cardiovascular innovative devices in China and the United States, supported by the world's top cardiovascular interventional medical device inventors, with a global innovative vision, focusing on the combination of medicine and industry to solve clinical pain points, and tapping major unmet clinical needs in the field of heart failure treatment. With a new generation of non intravascular blood contact ventricular assist devices as the first product, it will bring better More comprehensive interventional treatment solutions.
MORE：